Enhanced expression of iNOS intratumorally and at the immunization site after immunization with IFNγ-secreting rat glioma cells

Journal of Neuroimmunology

Volumn 123, Issue 1-2, 2002, Pages 135-143

  Johansson, Anna C ^a   Hegardt, Pontus ^a,b   Janelidze, Shorena ^a,b   Visse, Edward ^a,b   Widegren, Bengt ^a   Siesjö, Peter ^b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

IFN ; Immunohistochemistry; iNOS; NO; Rat glioma; Therapeutic immunization

Indexed keywords

GAMMA INTERFERON; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; GLIOMA CELL; IMMUNE RESPONSE; IMMUNIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; BRAIN NEOPLASMS; CELLS, CULTURED; GLIOMA; IMMUNIZATION; INTERFERON TYPE II; LYMPH NODES; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PHAGOCYTOSIS; RATS; RATS, INBRED F344; SKIN; SPLEEN;

EID: 0036190577     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(01)00468-4     Document Type: Article

References (41)

1. Nitric oxide production is required for murine resident peritoneal macrophages to suppress mitogen-stimulated T cell proliferation. Role of IFN-gamma in the induction of the nitric oxide-synthesizing pathway
2. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2
3. Nitric oxide suppresses human T lymphocytes proliferation through IFN-gamma-dependent and IFN-gamma-independent induction of apoptosis
4. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF
5. The expression of nitric oxide synthases in human brain tumors and peritumoral areas
6. Nitric oxide inhibits the secretion of T-helper 1- and T-helper 2-associated cytokines in activated human T cells
7. Zinc finger transcription factors as molecular targets for nitric oxide-mediated immunosuppression: Inhibition of IL-2 gene expression in murine lymphocytes
8. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway
9. Cellular responses to interferon-gamma
10. Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity
11. Role of tumor cell apoptosis in tumor antigen migration to the draining lymph nodes
12. Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor
13. Expression of nitric oxide synthase in human central nervous system tumors
14. The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduce expression of the inducible nitric oxide synthase gene
15. Immune defects observed in patients with primary malignant brain tumors
16. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy
17. Nitric oxide synthase expression in glial cells: Suppression by tyrosine kinase inhibitors
18. Temporal profiles and cellular sources of three nitric oxide synthase isoforms in the brain after experimental contusion
19. Nitric-oxide-dependent systemic immunosuppression in animals with progressively growing malignant gliomas
20. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells
21. Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma
22. Dendritic cells containing apoptopic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis
23. Immune suppression by recombinant interleukin (rIL)-12 involves interferon gamma induction of nitric oxide synthase 2 (iNOS) activity: Inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect
24. Nitric oxide in autoimmune disease: Cytotoxic or regulatory mediator?
25. Nitric oxide: Cytotoxicity versus cytoprotection - How, why, when, and where?
26. Synergistic cytokine-induced nitric oxide production in human alveolar epithelial cells
27. Expression of nitric oxide synthase isozymes (NOS I-III) by immunohistochemistry and DNA in situ hybridization. Correlation with macrophage presence, vascular endothelial growth factor (VEGF) and oedema volumetric data in 220 glioblastomas
28. Nitric oxide and macrophage function
29. Augmentation of an antitumor CTL response in vivo by inhibition of suppressor macrophage nitric oxide
30. TGF-beta-independent induction of immunogenicity by decorin gene transfer in human malignant glioma cells
31. Inducible nitric oxide synthase: What difference does it make?
32. Nitric oxide synthases: Roles, tolls, and controls
33. Effects of nitric oxide on the induction and differentiation of Th1 cells
34. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors
35. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
36. Immunization with mutagen-treated (tum-) cells causes rejection of nonimmunogenic rat glioma isografts
37. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
38. Immune-inflammatory mechanisms in IFN gamma-mediated anti-tumor activity
39. Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-gamma, interleukin-7, or B7-1 transfected tumor cells
40. Immunohistochemical analysis of glioma-infiltrating leucocytes after peripheral therapeutic immunization with interferon-gamma-transfected glioma cells
41. The physiology of lymphocyte migration through the single lymph node in vivo